The Destiny-Lung02 study
Prof dr Pasi Jänne, medical oncologist at the Dana Farber Cancer Institute, Boston, MA, USA presented the primary results of the DESTINY-Lung02 study evaluating 2 doses of trastuzumab deruxtecan (T-DXd) in patients with HER2-mutant metastatic non-small cell lung cancer (NSCLC). Both T-DXd 5.4 and 6.4 mg/kg showed strong and durable responses. The safety profile was acceptable and generally manageable at both doses and favored the 5.4 mg/kg dose. Prof Jänne concluded that this primary analysis support the use of T-DXd 5.4 mg/kg for patients with previously treated HER2m NSCLC and reinforces T-DXd as the standard of care in this patient population.
With the educational support of:
